Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

NICE, the NHS, and Cancer Drugs

NICE, the NHS, and Cancer Drugs This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

NICE, the NHS, and Cancer Drugs

Dillon, Andrew; Landells, Linda J.
JAMA , Volume 319 (8) – Feb 27, 2018
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/nice-the-nhs-and-cancer-drugs-DWhDqzxCzl

References (3)

Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.20552
pmid
29387883
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.

Journal

JAMA – American Medical Association

Published: Feb 27, 2018

There are no references for this article.